Lv1
90 积分 2022-01-26 加入
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis
2个月前
已完结
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance
2个月前
已完结
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance
2个月前
已完结
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy
2个月前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
3个月前
已完结
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
3个月前
已关闭
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer
3个月前
已完结
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
3个月前
已关闭
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial
4个月前
已完结
皖公网安备34019202002308
